



HAL
open science

Different clinical outcomes of *Entamoeba histolytica* in Malaysia: does genetic diversity exist?

Tengku Shahrul Anuar, Hesham M Al-Mekhlafi, Mohamed Kamel Abdul Ghani, Siti Nor Azreen, Fatmah Md Salleh, Nuraffini Ghazali, Mekadina Bernadus, Norhayati Moktar

► **To cite this version:**

Tengku Shahrul Anuar, Hesham M Al-Mekhlafi, Mohamed Kamel Abdul Ghani, Siti Nor Azreen, Fatmah Md Salleh, et al.. Different clinical outcomes of *Entamoeba histolytica* in Malaysia: does genetic diversity exist?. Korean Journal of Parasitology, 2013, 51 (2), pp.231-6. 10.3347/kjp.2013.51.2.231 . hal-01046941

HAL Id: hal-01046941

<https://hal.science/hal-01046941>

Submitted on 24 Jul 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Different Clinical Outcomes of *Entamoeba histolytica* in Malaysia: Does Genetic Diversity Exist?

Tengku Shahrul Anuar¹, Hesham M. Al-Mekhlafi², Mohamed Kamel Abdul Ghani³, Siti Nor Azreen¹, Fatmah Md Salleh¹, Nuraffini Ghazali¹, Mekadina Bernadus¹ and Norhayati Moktar^{1,*}

¹Department of Parasitology & Medical Entomology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia; ²Department of Parasitology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia; ³Programme of Biomedical Sciences, School of Diagnostic and Applied Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia

Abstract: The present study was conducted to investigate the clinical outcomes of *Entamoeba histolytica* infection in symptomatic and asymptomatic Orang Asli (aborigine) communities in Malaysia. Examination was performed on 500 stool samples obtained from Orang Asli communities in 3 different states using formalin-ether concentration, trichrome staining, and single-round PCR techniques. Out of 500 stool samples, single infection of *E. histolytica*, *Entamoeba dispar*, and *Entamoeba moshkovskii* was identified in 3.2%, 13.4%, and 1%, respectively. In addition, 10 samples had mixed infections with *E. histolytica* and *E. dispar*. Six samples containing *E. dispar* were also positive for *E. moshkovskii*, and only 2 samples had *E. histolytica* in association with *E. dispar* and *E. moshkovskii*. Seventeen *E. histolytica*-positive samples were from symptomatic subjects, whereas the remaining 11 samples came from asymptomatic subjects. These findings suggest a predominant distribution of pathogenic potential of *E. histolytica* strains in this community. Therefore, further studies on genotyping of *E. histolytica* is required, to find out association between *E. histolytica* genotype and the outcome of the infection.

Key words: *Entamoeba histolytica*, symptomatic, asymptomatic, clinical outcome, genetic diversity, Malaysia

Entamoeba histolytica is an enteric protozoan parasite that exists in either trophozoite or cyst form. The motile form (trophozoites) multiplies by binary fission and differentiates to the resistant form (cysts) that is responsible for transmission of the infection. Cysts are excreted in stools and may be ingested by a new host via contaminated water or food [1]. In the 1980s, the global prevalence of amebiasis was estimated to be approximately 10% of the world's population. Of these, approximately 90% were estimated to be asymptomatic carriers while only 10% will be developed to invasive amebiasis, leading to 110,000 deaths per year [2].

E. histolytica is capable of invading the intestinal mucosa and may spread to other extraintestinal organs, mainly the liver and rarely the kidneys, lungs, and brain. Thus, *E. histolytica* is unique among the intestinal amebae because it is able to in-

vade tissue and clinical presentation may range from an asymptomatic infection to a disseminated fatal disease. Depending on the area of endemicity, the incubation period may vary from a few days to months [3]. Furthermore, even considering only *E. histolytica* infection, invasive amebiasis appears to be a relatively rare outcome of the infection. Therefore, the main objective of the present study was to investigate the clinical outcomes of *E. histolytica* infection in symptomatic and asymptomatic Orang Asli (aborigine) communities in Malaysia.

A total of 500 stool samples, comprising of 150 from Negeri Sembilan state, 139 from Perak state, and 211 from Pahang state in Peninsular Malaysia (Fig. 1) were collected over the period from June to December 2011. The participants were asked by a trained field assistant to answer to a pre-tested questionnaire developed to elicit information on the demographic data, socioeconomic status, signs and symptoms, and medical treatment. After informed consent was obtained and questionnaire answered, all participants were then requested to provide a sufficiently large stool sample in a wide mouth screw-capped containers pre-labeled with their names and coded to enable both microscopic examination and molecular method to be

•Received 13 November 2012, revised 23 January 2013, accepted 10 February 2013.

*Corresponding author (syahbasree@yahoo.com)

© 2013, Korean Society for Parasitology and Tropical Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



Fig. 1. Map showing the location of the villages in Peninsular Malaysia involved in the study (triangles).

performed. Approximately 5 g of each stool sample was kept into a 15-ml centrifuge tube containing 3 ml polyvinyl alcohol. The samples were subjected to modified trichrome staining [4], while another half of the samples were kept unfixed and stored at 4°C upon arrival at the laboratory for further analysis by formalin-ether concentration [5]. Samples were considered microscopically positive if cysts and/or trophozoites of *E. histolytica/dispar/moshkovskii* were detected in at least 1 of the 2 techniques and negative if absent in all 2 techniques.

All stool samples were further characterized using molecular methods. Genomic DNA was extracted directly from all unfixed stool samples using QIAamp Stool DNA extraction kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. The final DNA elution was made in 70 µl of elution buffer and stored at -20°C until required for PCR amplification.

A single-round PCR assay and primer sets were used as described previously [6]. The sequence of the forward primer used (EntaF) was conserved in all 3 *Entamoeba* spp., whereas the specific reverse primers EhR, EdR, and EmR were specific for *E. histolytica*, *E. dispar*, and *E. moshkovskii*, respectively. The expected products were 166 bp (*E. histolytica*), 580 bp (*E.*

moshkovskii), and 752 bp (*E. dispar*). DNA isolated from axenically grown *E. histolytica* HM-1:IMSS, *E. dispar* SAW 760, and *E. moshkovskii* Laredo was used as positive controls. All of these control DNA were a courtesy of Dr. Graham Clark (London School of Hygiene and Tropical Medicine, London, UK). Amplification of each species-specific DNA fragment started with an initial denaturation at 94°C for 3 min, followed by 30 cycles of 94°C for 1 min, 58°C for 1 min and 72°C for 1 min, with a final extension at 72°C for 7 min. Its amplified products were analyzed by electrophoresis in 1.5% agarose gels and stained with GelRed (0.1 µl/ml, Biotium).

The PCR products were sequenced in both directions using the same primer sets as in the respective PCR assay using an ABI 3730XL sequencer (Bioneer Corporation, Seoul, Korea). Forward and reverse sequences were edited, manually aligned, and the consensus sequence was created for each sample using the BioEdit Sequence Alignment Search Tool (BLAST) to the National Centre for Biotechnology Information (NCBI) reference sequences (<http://www.ncbi.nlm.nih.gov/BLAST>). The *E. histolytica* (GenBank accession no. X56991) reference sequence was used in the analysis.

Prior to stool and data collections, the study protocol (reference no. UKM 1.5.3.5/244/FF-165-2011) was reviewed and approved by the Ethics Committee of Universiti Kebangsaan Malaysia Medical Centre (UKMMC) and permission for field works were obtained from the Ministry of Rural and Regional Development, Malaysia.

A total of 93 (18.6%) samples were microscopically positive for cysts and/or trophozoites of *E. histolytica/dispar/moshkovskii*, either singly or in combination with other protozoan parasites. Of the 93 microscopy-positive samples, single isolation of *E. histolytica/dispar/moshkovskii* was found in 19 (20.4%) samples, whereas the other 74 (79.6%) were mixed with 2 or more different protozoan species. Of the 500 Orang Asli who provided samples, 56.2% (281) were females and 43.8% (219) were males.

Of microscopy-positive stool samples containing *E. histolytica/dispar/moshkovskii*, PCR products were detected in 63 (67.7%) samples, whereas 30 (32.3%) were found to be negative (Table 1). Of the 30 PCR-negative samples, 13 were positive for cysts, and 17 contained both trophozoites and cysts of *E. histolytica/dispar/moshkovskii*. On the other hand, DNA products were detected in 10.6% (43/407) of microscopy-negative stool samples. Overall, PCR products were detected in 21.2% (106/500) of the tested samples (Fig. 2), whereas 78.8% (394/500) were found

Table 1. Results of microscopic examination and single-round PCR performed on 500 stool samples

		Single-round PCR ^b						Negative	Total
		E. h	E. d	E. m	E. h + E. d	E. d + E. m	E. h + E. d + E. m		
Microscopic examination ^a	Positive	4	51	1	3	4	0	30	93
	Negative	12	16	4	7	2	2	364	407
	Total	16	67	5	10	6	2	394	500

^aSpecies cannot be distinguished.

^bSpecies detected by PCR.

E.h=*Entamoeba histolytica*; E.d=*Entamoeba dispar*; E.m=*Entamoeba moshkovskii*.




Fig. 2. Agarose gel electrophoresis of *Entamoeba* species using single-round PCR. Lane M, 100-bp ladder DNA marker; Lane 1, *E. histolytica* HM-1:IMSS positive control; Lane 2, *E. moshkovskii* Laredo positive control; Lane 3, *E. dispar* SAW 760 positive control; Lanes 4 and 5, *E. histolytica* isolates; Lanes 6 to 8, mixed infections of *E. dispar* and *E. moshkovskii* isolates; Lane 9, *E. dispar* isolate; Lanes 10 to 12, *E. moshkovskii* isolates; Lane 13, negative control (DNase free water, Fermentas).

to be negative by a single-round PCR assay. Of the 106 PCR-positive samples, 3.2% were shown to contain single isolation of *E. histolytica*, 13.4% contained *E. dispar*, and only 1.0% contained *E. moshkovskii*. Mixed infections with *E. histolytica* and *E. dispar* were found in 2% of the samples. Six (1.2%) samples contained *E. dispar* and *E. moshkovskii*. PCR assay also detected 0.4% (2) of mixed infections by all the 3 species.

Representative PCR products were sequenced in both directions from 16 samples of *E. histolytica*. Sequences of all 16 single isolations of *E. histolytica* showed high similarity (98-99%) to the *E. histolytica* sequences in GenBank (accession no. X56991). The 28 positive samples of *E. histolytica* were from 10 (35.7%) males and 18 (64.3%) females, aged between 2 and 61 years. Seventeen *E. histolytica*-positive samples were from symptomatic individuals, whereas the remaining 11 samples came from asymptomatic individuals. Out of 17, only 7 individuals had *E. histolytica* in association with pathogenic parasites such as *Giardia intestinalis* and soil-transmitted helminths (STHs) (Table 2).

E. histolytica is a common human pathogen that causes a spectrum of disease ranging from a commensal state in asymptomatic carriers to fulminant diarrhea or extraintestinal abscess formation. Indeed, less than 1 in 10 infections are now thought to result in intestinal or extraintestinal symptoms in humans. The invasive strain of *E. histolytica* can cause ulceration of the intestinal epithelium and may penetrate the bowel wall to form extraintestinal abscess, especially in the liver. Several molecular types thought to correlate with the virulent phenotype have been partially characterized [7]. The pathogenic characteristic of several human *E. histolytica* isolates studied in different laboratories and tested in vivo and in vitro for their pathogenic capacity showed differences that can be associated with variations in the virulence potential between strains [8]. In addition, the advancements in molecular biology and genetics, now applied to amebic research, allow more precise search on intraspecies diversity markers associated with intestinal or extraintestinal invasive capacity of these protozoa in humans [9].

The present study demonstrated that 17 *E. histolytica*-positive samples were isolated from symptomatic subjects. The history of diarrhea, abdominal pain, vomiting, and other associated systemic symptoms such as fever, loss of appetite, and loss of weight were commonly seen in 61% individuals infected with *E. histolytica*. Likewise, a more recent study conducted in Turkey reported that almost all (13/14) of the children with *E. histolytica* infection had clinical symptoms, dysentery, cramping abdominal pain, diarrhea, flatulence, vomiting, and headache [10]. In the Netherlands, the researchers revealed that 3/4 of the *E. histolytica* carriers reported with abdominal complaints or diarrhea [11]. This finding is parallel with a study conducted in Sweden which demonstrated 10 patients that were diagnosed positive for *E. histolytica* showed different clinical manifestations ranging from diarrhea, abdominal pain, nausea, and constipation [12]. A study carried out in Egypt reported that the main symptoms among *E. histolytica*-dysenteric

Table 2. Clinical details of 28 subjects positive for *E. histolytica* by single-round PCR

Age	Sex	Microscopy	PCR	Symptoms	Other parasites
30	F	Negative	E.h	Asymptomatic	<i>Trichuris trichiura</i>
40	M	Negative	E.h	Asymptomatic	<i>Trichuris trichiura</i>
5	M	Negative	E.h	Asymptomatic	<i>Chilomastix mesnili</i> , <i>Entamoeba hartmanni</i> , <i>Trichuris trichiura</i>
9	F	Negative	E.h	Asymptomatic	<i>Entamoeba hartmanni</i> , <i>Iodamoeba butschlii</i> , <i>Trichuris trichiura</i> , <i>Ascaris lumbricoides</i>
7	F	Negative	E.h	Asymptomatic	<i>Blastocystis hominis</i>
55	F	Positive	E.h	Diarrhea, abdominal pain	None
13	F	Negative	E.h	Diarrhea, loss of appetite	None
10	F	Negative	E.h	Abdominal pain, fever	None
8	M	Negative	E.h	Abdominal pain	None
11	F	Positive	E.h	Diarrhea	None
60	M	Positive	E.h	Loss of weight	<i>Trichuris trichiura</i> , Hookworm
2	F	Negative	E.h	Loss of weight, loss of appetite	<i>Trichuris trichiura</i>
12	F	Negative	E.h	Vomiting	<i>Trichuris trichiura</i> , <i>Ascaris lumbricoides</i> , Hookworm
30	F	Negative	E.h	Diarrhea, fever	<i>Trichuris trichiura</i>
31	M	Positive	E.h	Diarrhea, abdominal pain	<i>Entamoeba coli</i>
37	F	Negative	E.h	Fever	<i>Endolimax nana</i>
5	M	Negative	E.h + E.d	Asymptomatic	<i>Giardia intestinalis</i> , <i>Trichuris trichiura</i> , Hookworm
6	M	Negative	E.h + E.d	Asymptomatic	<i>Giardia intestinalis</i> , <i>Trichuris trichiura</i>
11	M	Negative	E.h + E.d	Asymptomatic	<i>Trichuris trichiura</i> , <i>Ascaris lumbricoides</i>
37	F	Negative	E.h + E.d	Asymptomatic	None
20	F	Positive	E.h + E.d	Vomiting	<i>Entamoeba hartmanni</i> , <i>Giardia intestinalis</i>
4	M	Negative	E.h + E.d	Diarrhea, loss of weight, abdominal pain	<i>Giardia intestinalis</i> , <i>Trichuris trichiura</i>
61	F	Negative	E.h + E.d	Abdominal pain, fever	<i>Ascaris lumbricoides</i>
45	F	Negative	E.h + E.d	Diarrhea, loss of appetite	<i>Blastocystis hominis</i> , <i>Iodamoeba butschlii</i>
9	M	Positive	E.h + E.d	Diarrhea	<i>Blastocystis hominis</i>
30	F	Positive	E.h + E.d	Abdominal pain	<i>Entamoeba hartmanni</i> , <i>Endolimax nana</i>
12	F	Negative	E.h + E.d + E.m	Asymptomatic	None
6	F	Negative	E.h + E.d + E.m	Asymptomatic	<i>Entamoeba coli</i> , <i>Entamoeba hartmanni</i>

E.h=*Entamoeba histolytica*; E.d=*Entamoeba dispar*; E.m=*Entamoeba moshkovskii*.

patients were colic and distention (64.3%), easy fatigue (57.1%) followed by tenesmus (50%), loss of weight (42.9%), and anorexia and vomiting (21.4%) [13], whereby the main presenting symptoms among non-dysenteric patients were colic and distention (66.7%) followed by fever (50%) and easy fatigue (16.7%). In Mexico, a study done by Redondo et al. [14] found a high correlation (98%) between clinical symptoms and *E. histolytica* infection and that the diagnosis of invasive amebae indicated that treatment should be done. The symptoms included dysentery, diarrhea, abdominal pain, and vomiting. Kebeda et al. [15] conducted a study among Ethiopian children showing that the most common complaints of *E. histolytica* infection were abdominal pain, tenesmus, mucoid bloody diarrhea, and distention, whereas fever, loss of weight, and constipation were less common.

However, there is a disparity between the present finding

with previous studies which found a higher prevalence rate of *E. histolytica* asymptomatic infection in a rural Mexican community [16]. Likewise, a study conducted in the northern Philippines also reported that all of the *E. histolytica*-positive subjects were asymptomatic [17]. Furthermore, Haque et al. [18] reported that asymptomatic *E. histolytica* infection was common among preschool children in the urban slum of Dhaka, Bangladesh. This is consistent with several reports from endemic areas which showed that most *E. histolytica* infections are asymptomatic [19]. These findings were in agreement with the epidemiologic assertion before the characterization of *E. histolytica* and *E. dispar* species in the 1990s; 90% of *E. histolytica*-infected subjects are asymptomatic cyst passers [2].

In our study, diarrhea and other gastroenteritis symptoms were significantly associated with *E. histolytica* infection. The cause-effect relationship of *E. histolytica* with the clinical symp-

toms could not be determined in this present study due to the limitation of the design and no attempt to rule out other bacterial and viral infections. Besides these, it has long been known that not all *E. histolytica* infections lead to a clinical disease. The variables that are responsible for determining the different outcomes are still largely unknown. At present, we do not know whether some *E. histolytica* strains are intrinsically more virulent than others, but it has been reported that the outcome of *E. histolytica* infection may depend on several factors among which the genetic characteristics of the specific pathogen have been identified as an important factor. Few polymorphic genetic loci have been identified and targeted to aid in the study of the population structure of *E. histolytica* strains and their possible relationships with the parasite's virulence and disease outcome [20]. In order to investigate whether there is any link between the parasite and outcome of the infection, a reliable method for genotyping of the organism is required. Furthermore, in endemic areas of intestinal parasitic infections, mixed infections with STHs and other pathogenic protozoa that were also responsible for gastroenteritis symptoms were commonly observed. In this study, STHs, predominantly *Trichuris trichiura*, and *Giardia intestinalis* were detected in 42% (7/17) of symptomatic *E. histolytica*-positive subjects. Thus, these intestinal parasites may also account for the subjects' clinical symptoms.

In 30 samples positive for *E. histolytica/dispar/moshkovskii* by microscopy, we were unable to amplify DNA from any member of the *E. histolytica/dispar/moshkovskii* with the primers used and no inhibition of PCR was observed in control experiments. These results can potentially be explained by the presence of other *Entamoeba* species, which were detected by microscopy but not by PCR, or the presence of a low number of parasites in the sample, which fell below the detection limit of PCR. Another reason for this could be the fact that a majority of these samples (17/30) contained trophozoites that could have degenerated with time.

The discovery of low prevalence of *E. histolytica* infection in Orang Asli communities in this study indicates that this infection is not a public health problem in this community. However, identification of a high proportion of clinical symptoms among individuals positive for *E. histolytica* warrants further study to determine the causes. Therefore, immensely large scale, deliberate, and organized molecular genotyping studies are required to investigate whether there is any link between *E. histolytica* and the outcome of the infection in these communities.

ACKNOWLEDGMENTS

We sincerely thank Dr. Graham Clark (London School of Hygiene and Tropical Medicine, UK) for providing us with the lyophilized DNA of standard cultures of *E. histolytica* HM-1: IMSS, *E. dispar* SAW 760, and *E. moshkovskii* Laredo. We gratefully acknowledge the Ministry of Rural and Regional Development Malaysia for granting us permission to conduct this research.

We also thank all the participants from the Parit Gong village, Pasu village, Pian village, Bagan Balak village, Sungai Bannun village, Desa Damai village, Sungai Raba village, and Pengkalan Permai village for their commitment and contribution in providing their stool samples.

This work was supported in part by the UKMMC Fundamental Research Grant (FF-165-2011) and Special Research University Grant (UKM-GUP-2011-316) from Universiti Kebangsaan Malaysia.

REFERENCES

1. Marshall MM, Naumovitz D, Ortega Y, Sterling CR. Waterborne protozoan pathogens. *Clin Microbiol Rev* 1997; 10: 67-85.
2. Walsh JA. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. *Rev Infect Dis* 1986; 8: 228-238.
3. Ravdin JI. State of the art of clinical article. *Clin Infect Dis* 1995; 20: 1453-1466.
4. Salleh FM, Anuar TS, Yasin AM, Mokhtar N. Wintergreen oil: a novel method in Wheatley's trichrome staining technique. *J Microbiol Methods* 2012; 91: 174-178.
5. Fleck SL, Moody AH. *Diagnostic Technique in Medical Parasitology*. 11th ed. Cambridge, UK: Cambridge UP; 1993.
6. Hamzah Z, Petmitr S, Mungthin M, Leelayoova S, Chavalitshe-winkoon-Petmitr P. Differential detection of *Entamoeba histolytica*, *Entamoeba dispar* and *Entamoeba moshkovskii* by a single-round PCR assay. *J Clin Microbiol* 2006; 43: 3196-3200.
7. Edman U, Meraz MA, Rausser S, Agabian N, Meza I. Characterization of an immune-dominant variable surface antigen from pathogenic and nonpathogenic *Entamoeba histolytica*. *J Exp Med* 1990; 172: 879-888.
8. Tsutsumi V, Ramirez-Rosales A, Lanz-Mendoza H, Shibayama M, Chavez B, Rangel-Lopez E, Martinez-Palomo A. *Entamoeba histolytica*: erythrophagocytosis, collagenolysis and liver abscess production as virulence markers. *Trans R Soc Trop Med Hyg* 1992; 86: 170-172.
9. Ramos F, Moran P, Gonzalez E, Garcia G, Ramiro M, Gomez A, de Leon Mdel C, Melendro EI, Valadez A, Ximenez C. High prevalence rate of *Entamoeba histolytica* asymptomatic infection

- in a rural Mexican community. *Am J Trop Med Hyg* 2005; 73: 87-91.
10. Ozer TT, Yula E, Deveci O, Tekin A, Durmaz S, Yanik K. Investigation of *Entamoeba histolytica* in stool specimens by direct microscopic examination and ELISA in a hospital. *Dic Tip Derg* 2011; 38: 294-297.
 11. Visser LG, Verweij JJ, Esbroeck MV, Edeling WM, Clerinx J, Polderman AM. Diagnostic methods for differentiation of *Entamoeba histolytica* and *Entamoeba dispar* in carriers: performance and clinical implications in a non-endemic setting. *Int J Med Microbiol* 2006; 296: 397-403.
 12. Lebbad M, Svard SG. PCR differentiation of *Entamoeba histolytica* and *Entamoeba dispar* from patients with amoeba infection initially diagnosed by microscopy. *Scand J Infect Dis* 2005; 37: 680-685.
 13. Rashed SM, Nasr MES, Abd-Allah KF, Eraky MA, Nagieb MM. Comparative study between PCR and microscopic examination in diagnosing *Entamoeba histolytica*. *J Egypt Soc Parasitol* 2011; 41: 89-98.
 14. Redondo RB, Laura G, Martinez M, George A. *Entamoeba histolytica* and *Entamoeba dispar*: differentiation by enzyme-linked immunosorbent assay (ELISA) and its clinical correlation with pediatric patients. *Rev Infect Dis* 2004; 23: 238-239.
 15. Kebede A, Verweij JJ, Endeshaw T, Messele T, Tasew G, Petros B, Polderman AM. The use of real-time PCR to identify *Entamoeba histolytica* and *Entamoeba dispar* infections in prisoners and primary-school children in Ethiopia. *Ann Trop Med Parasitol* 2004; 98: 43-48.
 16. Ramos F, Moran P, Gonzalez E, Garcia G, Rairo M, Gomez A, de Leon Mdel C, Melendro EI, Valadez A, Ximenez C. High prevalence rate of *Entamoeba histolytica* asymptomatic infection in a rural Mexican community. *Am J Trop Med Hyg* 2005; 73: 87-91.
 17. Rivera WL, Tachibana H, Kanbara H. Field study on the distribution of *Entamoeba histolytica* and *Entamoeba dispar* in the Northern Philippines as detected by the polymerase chain reaction. *Am J Trop Med Hyg* 1998; 59: 916-921.
 18. Haque R, Ali IKM, Petri WA Jr. Prevalence and immune response to *Entamoeba histolytica* infection in preschool children in Bangladesh. *Am J Trop Med Hyg* 1999; 60: 1031-1034.
 19. Ravdin JI, Jackson TFHG, Petri WA Jr, Murphy CE, Ungar BLP, Gathiram V, Skilogiannis J, Simjee AE. Association of serum antibodies to adherence lectin with invasive amebiasis and asymptomatic infection with pathogenic *Entamoeba histolytica*. *J Infect Dis* 1990; 162: 768-772.
 20. Paul J, Srivastava S, Bhattacharya S. Molecular methods for diagnosis of *Entamoeba histolytica* in a clinical setting: an overview. *Exp Parasitol* 2007; 116: 35-43.